Literature DB >> 26153112

Multicentre study of 18F-FDG-PET/CT prostate incidental uptake.

Francesco Bertagna1, Arnoldo Piccardo2, Bassam Dib2, Mattia Bertoli3, Federica Fracassi3, Giovanni Bosio3, Raffaele Giubbini3, Giorgio Biasiotto4, Luca Giovanella4,5, Giorgio Treglia4.   

Abstract

AIM: The purpose of our study was to establish the prevalence and pathological nature of fluorine-18-fluorodeoxyglucose (18F-FDG) prostate incidental uptake (PIU) among patients studied for non-prostate-malignant purposes in three nuclear medicine centres.
METHODS: We retrospectively evaluated 20,422 scans performed on male patients; all patients underwent 18F-FDG-PET/CT for purposes not related to prostate disease.
RESULTS: Among 20,422 patients PIU was identified for 280 (1.4 %) with an average age of 70 ± 10.7 years. Sixty-three of the 280 patients with PIU (22.5 %) underwent PSA dosage and biopsy to determine the nature of the incidental uptake. Thirty-five of the 63 (55.5 %) PIU were malignant whereas 28/63 (44.5 %) were benign. The average value of PSA for patients with benign PIU was 3.7 ± 2.8 ng/ml whereas it was 7.8 ± 8.2 ng/ml in patients with malignant PIU; this difference was statistically significant. For malignant lesions, the average lesion-to-liver SUVmax ratio was 2.9 ± 2.5 and the average lesion-to-blood-pool SUVmax ratio was 3.7 ± 2.5. For benign lesions, the average lesion-to-liver SUVmax ratio was 2.5 ± 1.7 and the average lesion-to-blood-pool SUVmax ratio was 3.5 ± 2.4; there was no statistically significant difference between lesion-to-liver and lesion-to-blood-pool SUVmax ratios for benign and malignant lesions.
CONCLUSION: Because PIU values are indicative of malignancy for a substantial percentage of patients, further investigation is required.

Entities:  

Keywords:  18F-FDG; Incidentaloma; PET/CT; Prostate

Mesh:

Substances:

Year:  2015        PMID: 26153112     DOI: 10.1007/s11604-015-0453-y

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  24 in total

1.  The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level.

Authors:  Ryogo Minamimoto; Hiroji Uemura; Futoshi Sano; Hideyuki Terao; Yoji Nagashima; Shoji Yamanaka; Kazuya Shizukuishi; Ukihide Tateishi; Yoshinobu Kubota; Tomio Inoue
Journal:  Ann Nucl Med       Date:  2010-10-08       Impact factor: 2.668

2.  Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT.

Authors:  Masato Shiiba; Keiichi Ishihara; Go Kimura; Tomoyuki Kuwako; Hisashi Yoshihara; Naohisa Yoshihara; Hidetaka Sato; Yukihiro Kondo; Shin-ichi Tsuchiya; Shin-ichiro Kumita
Journal:  Ann Nucl Med       Date:  2011-11-09       Impact factor: 2.668

3.  Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy.

Authors:  C Hofer; C Laubenbacher; T Block; J Breul; R Hartung; M Schwaiger
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

4.  Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography scans.

Authors:  Pil Moon Kang; Won Ik Seo; Sun Seong Lee; Sang Kyun Bae; Ho Sup Kwak; Kweonsik Min; Wansuk Kim; Dong Il Kang
Journal:  Asian Pac J Cancer Prev       Date:  2014

Review 5.  Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas.

Authors:  Francesco Bertagna; Giorgio Treglia; Arnoldo Piccardo; Raffaele Giubbini
Journal:  J Clin Endocrinol Metab       Date:  2012-08-17       Impact factor: 5.958

6.  Multicentric study on ¹⁸F-FDG-PET/CT breast incidental uptake in patients studied for non-breast malignant purposes.

Authors:  Francesco Bertagna; Laura Evangelista; Arnoldo Piccardo; Mattia Bertoli; Giovanni Bosio; Raffaele Giubbini; Emanuela Orlando; Giorgio Treglia
Journal:  Rev Esp Med Nucl Imagen Mol       Date:  2014-10-11       Impact factor: 1.359

7.  Fluorescent fructose derivatives for imaging breast cancer cells.

Authors:  Jelena Levi; Zhen Cheng; Olivier Gheysens; Manish Patel; Carmel T Chan; Yingbing Wang; Mohammad Namavari; Sanjiv Sam Gambhir
Journal:  Bioconjug Chem       Date:  2007-04-20       Impact factor: 4.774

8.  Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues.

Authors:  Alejandro Godoy; Viviana Ulloa; Federico Rodríguez; Karin Reinicke; Alejandro J Yañez; María de los Angeles García; Rodolfo A Medina; Mónica Carrasco; Sofía Barberis; Tamara Castro; Fernando Martínez; Ximena Koch; Juan Carlos Vera; María Teresa Poblete; Carlos D Figueroa; Bruno Peruzzo; Fernando Pérez; Francisco Nualart
Journal:  J Cell Physiol       Date:  2006-06       Impact factor: 6.384

9.  Prevalence and risk of cancer of incidental uptake in prostate identified by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography.

Authors:  Zhongyi Yang; Silong Hu; Jingyi Cheng; Junyan Xu; Wei Shi; Beiling Zhu; Yongping Zhang; Zhifeng Yao; Herong Pan; Yingjian Zhang
Journal:  Clin Imaging       Date:  2014-02-07       Impact factor: 1.605

10.  Incidental prostate ¹⁸F-FDG uptake without calcification indicates the possibility of prostate cancer.

Authors:  Hiroko Seino; Shuichi Ono; Hiroyuki Miura; Satoko Morohashi; Yunyan Wu; Fumiyasu Tsushima; Yoshihiro Takai; Hiroshi Kijima
Journal:  Oncol Rep       Date:  2014-02-04       Impact factor: 3.906

View more
  6 in total

1.  18F-FDG PET/CT in primary brain lymphoma.

Authors:  Domenico Albano; Giovanni Bosio; Mattia Bertoli; Raffaele Giubbini; Francesco Bertagna
Journal:  J Neurooncol       Date:  2017-11-17       Impact factor: 4.130

2.  Case: Incidental 18F-fluorodeoxyglucose-positron emission tomography/computed tomography prostate uptake: How should these patients be managed?

Authors:  Anne Couture; Mounsif Azizi; Daniel Taussky; Michael McCormack
Journal:  Can Urol Assoc J       Date:  2017-07-11       Impact factor: 1.862

Review 3.  Evidence-based management of incidental focal uptake of fluorodeoxyglucose on PET-CT.

Authors:  Deborah Pencharz; Malavika Nathan; Thomas L Wagner
Journal:  Br J Radiol       Date:  2018-01-31       Impact factor: 3.039

4.  Incidentalomas of the prostate detected by 18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.

Authors:  Miles P Mannas; Taeweon Lee; Maral Pourghiasian; Don C Wilson; Peter C Black
Journal:  Can Urol Assoc J       Date:  2019-11-29       Impact factor: 1.862

Review 5.  Update on advances in molecular PET in urological oncology.

Authors:  Kazuhiro Kitajima; Shingo Yamamoto; Kazuhito Fukushima; Ryogo Minamimoto; Takao Kamai; Hossein Jadvar
Journal:  Jpn J Radiol       Date:  2016-05-24       Impact factor: 2.374

6.  Evaluation of Blood Parameters Alteration Following Low-dose Radiation Induced by Myocardial Perfusion Imaging.

Authors:  M S Alavi; M A Okhovat; M Atefi; F Khajeh Rahimi; S Mortazavi; F Ebadi
Journal:  J Biomed Phys Eng       Date:  2018-06-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.